MINNEAPOLIS, Dec. 22, 2014 /PRNewswire/ -- Inspire Medical Systems, Inc. announced today that Tim Herbert, president and CEO, will present an overview of the company's business at the 33rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for 8:00 a.m. PT on Monday, January 12, 2015, at the Westin St. Francis Hotel in San Francisco.
Inspire Medical Systems developed and markets the first implantable device for obstructive sleep apnea (OSA). Approved by the U.S. Food and Drug Administration (FDA) in April 2014, Inspire Upper Airway Stimulation (UAS) therapy is an effective new treatment option for those with moderate to severe OSA who are unable or unwilling to use Continuous Positive Airway Pressure (CPAP). Inspire therapy delivers mild stimulation to key airway muscles which keeps the airway open during sleep.
Leading medical centers in the United States and Europe now offer Inspire therapy as part of their sleep apnea treatment programs. In the United States, commercial insurance payers have provided reimbursement for sleep apnea patients who meet the FDA indications for use for Inspire therapy. During the presentation, the company will review its accomplishments in 2014 and layout the business plans for 2015.
About Inspire therapy
Inspire® Upper Airway Stimulation (UAS) is an FDA approved treatment for people with moderate to severe OSA who are unable or unwilling to use CPAP. In contrast to CPAP, Inspire therapy works inside the body and with a patient's natural breathing process. The implanted system includes a small neurostimulator, a sensing lead and a stimulation lead. An external handheld Inspire sleep remote is used to turn the therapy on before bed and off upon waking. When activated, Inspire therapy senses breathing patterns and delivers mild stimulation to key airway muscles, which keeps the airway open during sleep. Patients implanted with Inspire therapy who participated in the STAR (Stimulation Therapy for Apnea Reduction) pivotal clinical trial experienced a 68 percent reduction in apnea events, a 70 percent reduction in oxygen desaturation events, and significant improvements in Quality of Life. These results were published in the January 9, 2014, issue of the New England Journal of Medicine. For more information, visit: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
About Inspire Medical Systems
Inspire Medical Systems, based in Minneapolis, Minn., was formed in 2007 when the technology and a significant intellectual property portfolio was spun-out of Medtronic (NYSE: MDT). Inspire Medical Systems has developed the FDA approved Inspire system for the treatment of Obstructive Sleep Apnea (OSA). Privately held, investors include Aperture Venture Partners, GDN Holdings, Johnson & Johnson, Kleiner Perkins Caufield & Byers, Medtronic, OrbiMed Advisors, Synergy Life Science Partners, TGap Ventures and US Venture Partners.
To learn more and to locate medical centers offering Inspire therapy, visit Inspire Medical Systems on the web at www.inspiresleep.com.
Media contacts: Helen Shik or Rachel Gross MSLGROUP Boston 781-684-0770 InspireMedical@mslgroup.com
SOURCE Inspire Medical Systems, Inc.